Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Grifols SA ( (GRFS) ) has provided an announcement.
On July 29, 2025, Grifols announced its half-year financial results for 2025, showcasing a 7% increase in revenues to EUR 3,677 million and a nearly fourfold rise in net profit to EUR 177 million, driven by strong performance in its Biopharma segment. The company also reduced its leverage ratio and reinstated a dividend payment, reflecting its commitment to shareholder returns. Grifols plans to launch Fibrinogen in Europe and the U.S. following FDA approval, and it has completed the delisting of Biotest from the Frankfurt Stock Exchange, increasing its equity stake to 80.32%. The company remains focused on its Value Creation Plan, leveraging its business model to mitigate potential impacts from trade tariffs.
The most recent analyst rating on (GRFS) stock is a Hold with a $10.30 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.
Spark’s Take on GRFS Stock
According to Spark, TipRanks’ AI Analyst, GRFS is a Outperform.
Grifols SA’s strong technical momentum and positive earnings call results drive the overall score, despite valuation concerns and financial performance challenges such as high leverage and low net profit margins. The robust growth in key segments and strategic initiatives to improve cash flow and profitability are significant positives.
To see Spark’s full report on GRFS stock, click here.
More about Grifols SA
Grifols, S.A. is a global healthcare company specializing in plasma-derived medicines. It operates in the biopharmaceutical industry, focusing on developing and producing therapies for patients with chronic and rare diseases. Grifols has a significant market presence in the United States, Europe, Egypt, and Canada, with a vertically integrated business model that enhances its operational resilience.
Average Trading Volume: 904,488
Technical Sentiment Signal: Buy
Current Market Cap: $8.67B
See more data about GRFS stock on TipRanks’ Stock Analysis page.